relapsed / refractory acute myeloid leukemia
Conditions
Interventions
Sponsors
The Second Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for recurrent/refractory AML:After complete remission (CR), peripheral blood reappears in leukemia cells or bone marrow primordial cells > 5% or extramedullary leukemia cell infiltration;2 courses of treatment after standard regimen were ineffective;after CR, after consolidation and intensive treatment, recurrence within 12 months;Patients who relapsed after 12 months but failed to respond to conventional chemotherapy;2 or more recurrences;Extramedullary leukemia persists. 2. Aged 18 to 65 years; 3. ECOG physical condition score was <= 3; 4. No serious complications, such as liver failure, renal failure, heart failure; 5. Must be able to understand the protocol, follow medical instructions and sign informed consent.
Exclusion criteria
Exclusion criteria: Patients who met any of the following criteria were excluded: 1. Who is receiving either a chemotherapy regimen or a targeted drug; 2. Major surgery (excluding diagnostic surgery) performed within the past 4 weeks; 3. Evidence of central nervous system disease; 4. Active infectious diseases, such as HBV, HCV, tuberculosis; 5. Serious diseases that may limit patients' participation in the trial (such as progressive infection, uncontrolled diabetes, severe cardiac insufficiency or myocardial infarction, liver and kidney dysfunction, etc); 6. Participating in other clinical trials or participating in clinical trials of other drugs within 3 months; 7. Women of childbearing age must have a negative pregnancy test and agree to use effective contraception during treatment and within a year thereafter 8. There are allergies or contraindications to any of the drugs involved in the protocol; 9. The researchers say it is not appropriate for patients who are treated with this regimen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug safety; | — |
Countries
China
Contacts
Public ContactYan Jinsong
The Second Affiliated Hospital of Dalian Medical University
Outcome results
None listed